Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.56 |
| ▸ | ADCY5 | O95622 | 5/20 | 0.55 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PI4KA | P42356 | 1/20 | 0.51 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.51 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.51 |
| ▸ | AHCY | P23526 | 2/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241928 | 1.00 | ALDH1A1 (0.58) | ALDH1A1ADORA2AADORA1ADORA2BADCY5 | |
| SCHEMBL14416686 | 0.89 | ALDH1A1 (0.60) | ALDH1A1ADORA2AADORA1ADORA2BADCY5 | |
| SCHEMBL12948655 | 0.88 | ADORA2A (0.56) | ALDH1A1ADORA2AADORA1ADORA2BADCY5 | |
| SCHEMBL12922452 | 0.86 | ALDH1A1 (0.62) | ALDH1A1ADORA2AADORA1ADORA2BADCY5 | |
| SCHEMBL11986908 | 0.86 | ALDH1A1 (0.62) | ALDH1A1ADORA2AADORA1ADORA2BADCY5 | |
| SCHEMBL982442 | 0.85 | ALDH1A1 (0.76) | ALDH1A1ADORA2AADORA1ADORA2BADCY5 | |
| SCHEMBL985545 | 0.80 | ADCY5 (0.63) | ALDH1A1ADORA2AADORA1ADORA2BADCY5 | |
| SCHEMBL8846447 | 0.80 | ALDH1A1 (0.60) | ALDH1A1ADORA2AADORA1ADORA2BADCY5 | |
| SCHEMBL11986907 | 0.79 | ADORA2A (0.59) | ALDH1A1ADORA2AADORA1ADORA2BADCY5 | |
| SCHEMBL12922453 | 0.78 | ADORA2A (0.67) | ALDH1A1ADORA2AADORA1ADORA2BPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | claimed |
| US-20250049780-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | claimed |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | claimed |
| WO-2025006568-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2025-01-02 | — | — | WO | claimed |
| US-12070455-B2 | Thienopyrrole compounds | GILEAD SCIENCES, INC. (US) | 2024-08-27 | — | — | US | claimed |
| EP-4398989-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-07-17 | — | — | EP | claimed |
| CN-117957234-A | Thienopyrrole compounds | 吉利德科学公司 | 2024-04-30 | — | — | CN | claimed |
| US-20240059673-A1 | SUBSTITUTED INDOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-02-22 | — | — | US | claimed |
| WO-2022140326-A1 | SUBSTITUTED INDOLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-06-30 | — | — | WO | claimed |
| WO-2022140325-A1 | 6-SUBSTITUTED INDOLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-06-30 | — | — | WO | claimed |
| EP-1613628-B1 | REVERSIBLE INHIBITORS OF S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE AND USES THEREOF | GEN ATOMICS (US) | 2013-11-20 | — | — | EP | claimed |
| US-8247549-B2 | Method for preparing 4-(6-amino-purin-9-YL)-2(S)-hydroxy-butyric acid methyl ester | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2012-08-21 | — | — | US | claimed |
| US-8168643-B2 | Multiple sclerosis; hemorrhagic virus infection, autoimmune diseases, autograft rejection, neoplasm, hyperhomocysteineuria, cardiovascular disease, stroke, Alzheimer's disease, or diabetes; can be used in combination with an anti-hemorrhagic viral infection agent, immunosuppressant | GENERAL ATOMICS (US) | 2012-05-01 | — | — | US | claimed |
| US-20110201810-A1 | Method for Preparing 4-[9-(6-Aminopurine)]-2-(S)-Hydroxyl-Butyric Acid Methyl Ester | Shanghai Institute of Materia Medica, Chinese Acad emy of Sciences (CN) | 2011-08-18 | — | — | US | claimed |
| US-7868011-B2 | Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus | GENERAL ATOMICS (US) | 2011-01-11 | — | — | US | claimed |
| EP-2230239-A1 | A METHOD FOR PREPARING 4-Ý9-(6-AMINOPURINE)¨-2-(S)-HYDROXYL-BUTYRIC ACID METHYL ESTER | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2010-09-22 | — | — | EP | claimed |
| US-7517887-B2 | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof | GENERAL ATOMICS (US) | 2009-04-14 | — | — | US | claimed |
| US-20070129386-A1 | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof | NINGBO ZIYUAN PHARMACEUTICALS, INC. (CN) | 2007-06-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049780-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | ALDH1A1 2343/4885ADORA2A 290/4885ADORA1 1383/4885 |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DUSP2, MKNK2, DUSP22 | ALDH1A1 4336/4885ADORA2A 2449/4885ADORA1 4465/4885 |
| US-20240059673-A1 | SUBSTITUTED INDOLE COMPOUNDS | SSB, IDO1, IDO2 | ALDH1A1 2448/4885ADORA2A 180/4885ADORA1 936/4885 |
| US-12070455-B2 | Thienopyrrole compounds | SSB, TPMT, LCP2 | ALDH1A1 2343/4885ADORA2A 290/4885ADORA1 1383/4885 |
| US-20110201810-A1 | Method for Preparing 4-[9-(6-Aminopurine)]-2-(S)-Hydroxyl-Butyric Acid Methyl Ester | TPMT, ATIC, UMPS | ALDH1A1 49/4885ADORA2A 208/4885ADORA1 300/4885 |
| US-20070129386-A1 | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof | AHCY, AHCYL1, BHMT | ALDH1A1 397/4885ADORA2A 72/4885ADORA1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.